Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Return on Sales (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Return on Sales for 8 consecutive years, with 13.94% as the latest value for Q1 2026.

  • Quarterly Return on Sales fell 1089.0% to 13.94% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 10.13% through Feb 2026, down 683.0% year-over-year, with the annual reading at 3.15% for FY2025, 40.0% up from the prior year.
  • Return on Sales for Q1 2026 was 13.94% at Nurix Therapeutics, down from 6.4% in the prior quarter.
  • The five-year high for Return on Sales was 0.79% in Q2 2023, with the low at 13.94% in Q1 2026.
  • Average Return on Sales over 5 years is 4.62%, with a median of 3.68% recorded in 2024.
  • The sharpest move saw Return on Sales surged 412bps in 2023, then crashed -1089bps in 2026.
  • Over 5 years, Return on Sales stood at 6.89% in 2022, then soared by 60bps to 2.77% in 2023, then dropped by -6bps to 2.93% in 2024, then crashed by -118bps to 6.4% in 2025, then plummeted by -118bps to 13.94% in 2026.
  • According to Business Quant data, Return on Sales over the past three periods came in at 13.94%, 6.4%, and 10.95% for Q1 2026, Q4 2025, and Q3 2025 respectively.